2000;61 Suppl 8:26-9; discussion 30.Jones B, Basson BR, Walker DJ, Crawford AM, Kinon BJ.Zhuo C, Xu Y, Liu S, Li J, Zheng Q, Gao X, Li S, Jing R, Song X, Yue W, Zhou C, Upthegrove R.Front Pharmacol. Third, although all four RCTs were rated as high-quality using the Jadad scale,Adjunctive ranitidine appears to be an effective and safe option for treating weight gain and negative symptoms in patients with schizophrenia. Second, only a few studies were available for the meta-analysis because the use of ranitidine for weight loss is off-label. RCTs reporting weight gain or metabolic side effects in patients with schizophrenia were included. 2014;16(3):PCC.13l01598. Epub 2013 Jul 30.Baptista T, ElFakih Y, Uzcátegui E, Sandia I, Tálamo E, Araujo de Baptista E, Beaulieu S.CNS Drugs. [Randomized, open label study on the use of ranitidine at different doses for the management of weight gain associated with olanzapine administration]Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trialsHypothalamic neuronal histamine regulates feeding circadian rhythm in ratsMetabolic side effects of antipsychotic drug treatment–pharmacological mechanismsSAGE Publications Ltd, unless otherwise noted. Factors that have been shown to contribute to the condition include: 1. citrus fruits; 2. tomato-based foods; 3. fried, fatty, and spicy foods; 4. obesity (extra pounds can put pressure on the lower esophageal sphincter); 5. drugs like calcium channel blockers, antihistamines, theophylline, and nitrates; 6. pregnancy; 7. eating before bedtime; 8. eating large meals; … Case reports/series, non-randomized or observational studies, reviews, and meta-analyses were excluded. If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Review side effects, drug interactions, dosage, and pregnancy safety information prior to taking any medication. Name must be less than 100 characters the site you are agreeing to our use of cookies. The weighted mean dosage of olanzapine was 19.1 mg/day (range = 5–30 mg/day) according to the available data in three RCTs.All four RCTs mentioned “randomized allocation” with a specific description, while the allocation concealment method was rated as “unclear” in one RCT and “high risk” in another RCT. Manuscript content on this site is licensed under Creative Commons Licenses. Clipboard, Search History, and several other advanced features are temporarily unavailable. RCTs reporting weight gain or metabolic side effects in patients with schizophrenia were included. 2008;22(6):477-95. doi: 10.2165/00023210-200822060-00003. In this study, concomitant administration of Ranitidine prevented or corrected weight gain in 59.6% of cases. This site uses cookies. 2013;2013:639391. doi: 10.1155/2013/639391. Not addressing this eventual treatment aspect of Olanzapine treatment may compromise the patient's health and his/her compliance with the pharmacological treatment indicated in serious psychiatric conditions. We wish to thank Prof. Phil Wiffen (Training Director of UK Cochrane Center) and Dr. Jun Xia (Cochrane Schizophrenia Group) for their systematic review courses.The authors declare that there is no conflict of interest.This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. The decision to use a molecule must be made taking into account its efficacy, efficiency and adverse effect profile. The weighted mean dosage of ranitidine was 339.5 mg/day (range = 150–600 mg/day). Please enable it to take advantage of the complete set of features! Furthermore, outcomes based on intention-to-treat analysis, if available, were recorded. The quality of evidence presented for the primary and secondary outcomes using the GRADE approach ranged from “low” (86%) to “moderate” (14%) (The weighted mean total Jadad score of the four RCTs was 3.9 (range = 3–5), and all studies were rated as high-quality (Jaded score of ≥3) (Compared with the control group, ranitidine was associated with a marginally significant decrease in the BMI (4 RCTs with 5 study arms, n = 312; WMD: −1.08 kg/mWith respect to clinical outcomes, only one RCT with two study arms used the PANSS. Patients treated additionally with Ranitidine at doses of 300 mg, a 0.9 kilogram weight gain ranging between -4 and +10.6 kg was observed, implying an average BMI change of 0.34. Furthermore, the Jadad scale (The weighted mean age was 32.4 years (range = 28.6–38.1 years), the mean percentage of male patients was 64% (range = 52.5%–89.3%), and the weighted mean illness duration (according to the available data in two RCTsThe weighted mean dosage of ranitidine was 339.5 mg/day (range = 150–600 mg/day). The inclusion of only 4 RCTs involving 315 patients and the limited or incomplete information lessen the confidence of the results and limit more comprehensive data exploration, such as meta-regression analyses.